These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23202523)

  • 21. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
    Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
    Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
    Díez-Domingo J; Baldó JM; Planelles-Catarino MV; Garcés-Sánchez M; Ubeda I; Jubert-Rosich A; Marès J; Garcia-Corbeira P; Moris P; Teko M; Vanden Abeele C; Gillard P
    Influenza Other Respir Viruses; 2015 Mar; 9(2):68-77. PubMed ID: 25652873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.
    Kosalaraksa P; Jeanfreau R; Frenette L; Drame M; Madariaga M; Innis BL; Godeaux O; Izurieta P; Vaughn DW
    J Infect Dis; 2015 Mar; 211(5):801-10. PubMed ID: 25293368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.
    van Doorn E; Liu H; Ben-Yedidia T; Hassin S; Visontai I; Norley S; Frijlink HW; Hak E
    Medicine (Baltimore); 2017 Mar; 96(11):e6339. PubMed ID: 28296763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
    Treanor JJ; Campbell JD; Zangwill KM; Rowe T; Wolff M
    N Engl J Med; 2006 Mar; 354(13):1343-51. PubMed ID: 16571878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
    Langley JM; Frenette L; Jeanfreau R; Halperin SA; Kyle M; Chu L; McNeil S; Dramé M; Moris P; Fries L; Vaughn DW
    Vaccine; 2015 Jan; 33(4):559-67. PubMed ID: 25448092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.
    Garg N; Tellier G; Vale N; Kluge J; Portman JL; Markowska A; Tussey L
    PLoS One; 2024; 19(6):e0303450. PubMed ID: 38843267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.
    Naruse T; Fukuda T; Tanabe T; Ichikawa M; Oda Y; Tochihara S; Kimachi K; Kino Y; Ueda K
    Vaccine; 2015 Nov; 33(45):6078-84. PubMed ID: 26409141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.
    López-Macías C; Ferat-Osorio E; Tenorio-Calvo A; Isibasi A; Talavera J; Arteaga-Ruiz O; Arriaga-Pizano L; Hickman SP; Allende M; Lenhard K; Pincus S; Connolly K; Raghunandan R; Smith G; Glenn G
    Vaccine; 2011 Oct; 29(44):7826-34. PubMed ID: 21816199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).
    Rudenko L; Desheva J; Korovkin S; Mironov A; Rekstin A; Grigorieva E; Donina S; Gambaryan A; Katlinsky A
    Influenza Other Respir Viruses; 2008 Nov; 2(6):203-9. PubMed ID: 19453396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.
    Taylor DN; Treanor JJ; Sheldon EA; Johnson C; Umlauf S; Song L; Kavita U; Liu G; Tussey L; Ozer K; Hofstaetter T; Shaw A
    Vaccine; 2012 Aug; 30(39):5761-9. PubMed ID: 22796139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.
    Brady RC; Treanor JJ; Atmar RL; Keitel WA; Edelman R; Chen WH; Winokur P; Belshe R; Graham IL; Noah DL; Guo K; Hill H
    Vaccine; 2009 Aug; 27(37):5091-5. PubMed ID: 19577636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.
    Shoji Y; Chichester JA; Jones M; Manceva SD; Damon E; Mett V; Musiychuk K; Bi H; Farrance C; Shamloul M; Kushnir N; Sharma S; Yusibov V
    Hum Vaccin; 2011; 7 Suppl():41-50. PubMed ID: 21266846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
    J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.